Full text is available at the source.
Abstract
The assessment focused on impurity profiles and potential immunogenicity of follow-on or compounded products for two GLP-1 receptor agonists: semaglutide and liraglutide.
- Multiple samples of semaglutide and liraglutide were evaluated.
- The study aimed to identify impurity profiles associated with these products.
- Potential immunogenicity of the samples was also assessed.
- Findings may inform safety and efficacy considerations for these glucagon-like peptide-1 receptor agonists.
Simplified
GLP-1 Therapies